Our findings suggest that at least for certain subgroups of AML some of the mutations, such as DEK-CAN or PML-RARα are able by themselves to aberrantly activate signaling pathways essential for the survival and the biology of the respective AML cell. The gene discussed is DEK; the disease is acute myeloid leukemia.